Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 8
2004 8
2005 20
2006 12
2007 7
2008 14
2009 13
2010 12
2011 11
2012 15
2013 12
2014 16
2015 17
2016 18
2017 10
2018 18
2019 35
2020 40
2021 44
2022 47
2023 37
2024 17

Text availability

Article attribute

Article type

Publication date

Search Results

371 results

Results by year

Filters applied: . Clear all
Page 1
Clinical pharmacokinetics of therapeutic monoclonal antibodies.
Keizer RJ, Huitema AD, Schellens JH, Beijnen JH. Keizer RJ, et al. Among authors: huitema ad. Clin Pharmacokinet. 2010 Aug;49(8):493-507. doi: 10.2165/11531280-000000000-00000. Clin Pharmacokinet. 2010. PMID: 20608753 Review.
Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology.
Bruin MAC, Sonke GS, Beijnen JH, Huitema ADR. Bruin MAC, et al. Among authors: huitema adr. Clin Pharmacokinet. 2022 Dec;61(12):1649-1675. doi: 10.1007/s40262-022-01167-6. Epub 2022 Oct 11. Clin Pharmacokinet. 2022. PMID: 36219340 Free PMC article. Review.
Therapeutic drug monitoring of oral targeted antineoplastic drugs.
Mueller-Schoell A, Groenland SL, Scherf-Clavel O, van Dyk M, Huisinga W, Michelet R, Jaehde U, Steeghs N, Huitema ADR, Kloft C. Mueller-Schoell A, et al. Among authors: huitema adr. Eur J Clin Pharmacol. 2021 Apr;77(4):441-464. doi: 10.1007/s00228-020-03014-8. Epub 2020 Nov 9. Eur J Clin Pharmacol. 2021. PMID: 33165648 Free PMC article. Review.
Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology.
van der Kleij MBA, Guchelaar NAD, Mathijssen RHJ, Versluis J, Huitema ADR, Koolen SLW, Steeghs N. van der Kleij MBA, et al. Among authors: huitema adr. Clin Pharmacokinet. 2023 Oct;62(10):1333-1364. doi: 10.1007/s40262-023-01293-9. Epub 2023 Aug 16. Clin Pharmacokinet. 2023. PMID: 37584840 Free PMC article. Review.
Predictive Value of Microdose Pharmacokinetics.
van Nuland M, Rosing H, Huitema ADR, Beijnen JH. van Nuland M, et al. Among authors: huitema adr. Clin Pharmacokinet. 2019 Oct;58(10):1221-1236. doi: 10.1007/s40262-019-00769-x. Clin Pharmacokinet. 2019. PMID: 31030372 Review.
Severe Immune-Related Enteritis after In Utero Exposure to Pembrolizumab.
Baarslag MA, Heimovaara JH, Borgers JSW, van Aerde KJ, Koenen HJPM, Smeets RL, Buitelaar PLM, Pluim D, Vos S, Henriet SSV, de Groot JWB, van Grotel M, Rosing H, Beijnen JH, Huitema ADR, Haanen JBAG, Amant F, Gierenz N. Baarslag MA, et al. Among authors: huitema adr. N Engl J Med. 2023 Nov 9;389(19):1790-1796. doi: 10.1056/NEJMoa2308135. N Engl J Med. 2023. PMID: 37937778
WEE1 inhibitor adavosertib in combination with carboplatin in advanced TP53 mutated ovarian cancer: A biomarker-enriched phase II study.
Embaby A, Kutzera J, Geenen JJ, Pluim D, Hofland I, Sanders J, Lopez-Yurda M, Beijnen JH, Huitema ADR, Witteveen PO, Steeghs N, van Haaften G, van Vugt MATM, de Ridder J, Opdam FL. Embaby A, et al. Among authors: huitema adr. Gynecol Oncol. 2023 Jul;174:239-246. doi: 10.1016/j.ygyno.2023.05.063. Epub 2023 May 24. Gynecol Oncol. 2023. PMID: 37236033 Clinical Trial.
371 results